Pregnancy: There are no adequate data from the use of Colistimethate sodium in pregnant women. Animal studies in rats and mice do not indicate teratogenic properties. However, single dose studies in human pregnancy show that Colistimethate crosses the placental barrier and there may be a risk of foetal toxicity if repeated doses are given to pregnant patients. Colistimethate should be used in pregnancy only if the benefit to the mother outweighs the potential risk to the foetus.
Lactation: Colistimethate is secreted in breast milk, and should be administered to breastfeeding women only when clearly needed.